Mount Vernon Cancer Centre, Northwood, UK.
Br J Radiol. 2013 Feb;86(1022):20120315. doi: 10.1259/bjr.20120315.
The increasing use of tomotherapy and volumetric-modulated arc therapy in UK centres will result in more centres choosing to use this technology in a clinical trial setting. The Radiotherapy Trials Quality Assurance (RTTQA) group has developed a new procedure to integrate into the UK intensity-modulated radiotherapy (IMRT) credentialing programme to cover rotational IMRT delivery techniques.
A planning test [three-dimensional treatment planning system (3DTPS)] was designed specifically for rotational IMRT techniques. The feasibility of using this test in the credentialing programme for rotational IMRT was validated by 10 experienced UK centres. The study included five centres using Varian RapidArc™ (RA) (Varian Medical Systems, Milpitas, CA), two using Elekta VMAT™ (VMAT) (Elekta Inc., Norcross, GA) and three using helical tomotherapy (HT) plans. Centres were asked to carry out their own in-house quality assurance (QA) for the plans submitted for this study. A survey was sent out to centres aiming to gather information on their experience in undertaking the exercise and their QA results.
All centres fulfilled the primary goal by achieving the dose constraints of the primary planning target volume and organ at risk. Seven centres (three RA, one VMAT and three HT plans) were able to fulfil the secondary goal. Among those seven centres, three centres (two RA and one VMAT plans) achieved the tertiary goal. The results of the survey indicated that the 3DTPS test is a clinically relevant and practical planning test to be used.
A planning test for rotational therapy techniques was developed for the RTTQA IMRT credentialing programme.
This study validated the feasibility of a 3DTPS test to be used as part of a credentialing programme for rotational IMRT techniques in the UK.
随着英国各中心越来越多地使用调强放疗和容积旋转调强弧形治疗技术，将会有更多的中心选择在临床试验中使用这项技术。放射治疗试验质量保证（RTTQA）小组开发了一种新的程序，以纳入英国调强放疗（IMRT）认证计划，涵盖旋转调强放疗的输送技术。
专门为旋转调强放疗技术设计了一个计划测试（三维治疗计划系统（3DTPS））。10 个经验丰富的英国中心验证了该测试在旋转调强放疗认证计划中的可行性。该研究包括 5 个使用瓦里安 RapidArc（RA）（瓦里安医疗系统，米尔皮塔斯，加利福尼亚州）的中心，2 个使用 Elekta VMAT（VMAT）（医科达公司，诺克罗斯，佐治亚州）的中心和 3 个使用螺旋断层放疗（HT）计划的中心。各中心被要求对提交给这项研究的计划进行自己的内部质量保证（QA）。向中心发送了一份调查，旨在收集他们在进行这项工作方面的经验和 QA 结果的信息。
所有中心都通过达到主要计划靶区和危及器官的剂量限制来实现主要目标。7 个中心（3 个 RA、1 个 VMAT 和 3 个 HT 计划）能够实现次要目标。在这 7 个中心中，有 3 个中心（2 个 RA 和 1 个 VMAT 计划）达到了第三级目标。调查结果表明，3DTPS 测试是一种具有临床相关性和实用性的计划测试方法。
为 RTTQA 的 IMRT 认证计划开发了旋转治疗技术的计划测试。
这项研究验证了 3DTPS 测试作为英国旋转调强放疗技术认证计划的一部分的可行性。
